{'52WeekChange': -0.62577105,
 'SandP52WeekChange': 0.0644362,
 'address1': '399 Binney Street',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.45,
 'askSize': 800,
 'averageDailyVolume10Day': 162137,
 'averageVolume': 255611,
 'averageVolume10days': 162137,
 'beta': 2.326987,
 'beta3Year': None,
 'bid': 5.44,
 'bidSize': 1200,
 'bookValue': 2.924,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.62,
 'dayLow': 5.34,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.628,
 'enterpriseToRevenue': None,
 'enterpriseValue': 292890528,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 6.203857,
 'fiftyTwoWeekHigh': 14.81,
 'fiftyTwoWeekLow': 3.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 35712075,
 'forwardEps': -1.87,
 'forwardPE': -2.9197862,
 'fromCurrency': None,
 'fullTimeEmployees': 195,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.10059,
 'heldPercentInstitutions': 0.97702,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/rubiustx.com',
 'longBusinessSummary': 'Rubius Therapeutics, Inc. focuses on the development '
                        'of red cell therapeutics (RCTs) for the treatment of '
                        'patients with severe diseases. The company is '
                        'developing various RCTs, such as RTX-134 for '
                        'treatment of phenylketonuria; RTX-Uricase for '
                        'treatment of chronic refractory gout; RTX-CBS for '
                        'treatment of homocystinuria; and RTX-OxOx for the '
                        'treatment of second-line hyperoxaluria. It is also '
                        'developing RTX-240 and RTX-224 for the treatment of '
                        'cancer; and RTX-aAPC to treat solid and hematological '
                        'cancers. In addition, the company is developing '
                        'RTX-T1D for treating type 1 diabetes; and RTX-PV for '
                        'treating pemphigus vulgaris. The company was founded '
                        'in 2013 and is headquartered in Cambridge, '
                        'Massachusetts.',
 'longName': 'Rubius Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 439399488,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_318913818',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -179363008,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.62,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-679-9600',
 'previousClose': 5.63,
 'priceHint': 2,
 'priceToBook': 1.867305,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.62,
 'regularMarketDayLow': 5.34,
 'regularMarketOpen': 5.62,
 'regularMarketPreviousClose': 5.63,
 'regularMarketPrice': 5.62,
 'regularMarketVolume': 120531,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 80476096,
 'sharesPercentSharesOut': 0.0946,
 'sharesShort': 7613550,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7030573,
 'shortName': 'Rubius Therapeutics, Inc.',
 'shortPercentOfFloat': 0.2886,
 'shortRatio': 25.09,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'RUBY',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.26,
 'twoHundredDayAverage': 6.5296764,
 'volume': 120531,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.rubiustx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}